-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Decreases By 41.3%
Short Interest in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Decreases By 41.3%
Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 378,600 shares, a decline of 41.3% from the June 15th total of 644,700 shares. Based on an average trading volume of 967,600 shares, the short-interest ratio is presently 0.4 days. Approximately 2.5% of the company's shares are sold short.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group cut their price target on shares of Finch Therapeutics Group from $29.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, April 4th.
Get Finch Therapeutics Group alerts:Institutional Trading of Finch Therapeutics Group
A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Finch Therapeutics Group by 19.4% during the 1st quarter. Renaissance Technologies LLC now owns 45,000 shares of the company's stock valued at $226,000 after buying an additional 7,314 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Finch Therapeutics Group by 2.3% during the 1st quarter. BlackRock Inc. now owns 404,931 shares of the company's stock valued at $2,038,000 after buying an additional 9,149 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Finch Therapeutics Group by 53.6% during the 1st quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company's stock valued at $189,000 after buying an additional 13,128 shares in the last quarter. Lake Street Advisors Group LLC boosted its holdings in shares of Finch Therapeutics Group by 16.2% during the 4th quarter. Lake Street Advisors Group LLC now owns 739,136 shares of the company's stock valued at $7,369,000 after buying an additional 102,941 shares in the last quarter. Finally, Light Street Capital Management LLC boosted its holdings in shares of Finch Therapeutics Group by 1.8% during the 4th quarter. Light Street Capital Management LLC now owns 811,731 shares of the company's stock valued at $8,093,000 after buying an additional 14,400 shares in the last quarter. Institutional investors own 22.68% of the company's stock.
Finch Therapeutics Group Stock Performance
NASDAQ:FNCH traded down $0.13 during trading hours on Friday, hitting $2.28. The company had a trading volume of 45,466 shares, compared to its average volume of 119,946. The stock has a 50-day moving average price of $2.47 and a 200 day moving average price of $5.14. Finch Therapeutics Group has a 52 week low of $1.71 and a 52 week high of $17.39.Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $0.35 million during the quarter. Finch Therapeutics Group had a negative net margin of 448.35% and a negative return on equity of 33.13%. As a group, research analysts predict that Finch Therapeutics Group will post -1.98 EPS for the current year.
Finch Therapeutics Group Company Profile
(Get Rating)
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.
Further Reading
- Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
- MarketBeat: Week in Review 7/11 – 7/15
- Should You Have These Two Banks In Your Portfolio?
- Is Coupang's Stock On The Verge Of A Turnaround?
- Why Shopify Stock Split...And is as Shoppable as Ever
- Verint Systems Stock is a Customer Engagement Play
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 378,600 shares, a decline of 41.3% from the June 15th total of 644,700 shares. Based on an average trading volume of 967,600 shares, the short-interest ratio is presently 0.4 days. Approximately 2.5% of the company's shares are sold short.
芬奇治疗集团公司(纳斯达克代码:FNCH-GET评级)是空头股数6月份大幅下降的目标。截至6月30日,空头股数共有378,600股,较6月15日的644,700股下降了41.3%。以96.76万股的平均成交量计算,目前短息比为0.4天。该公司约2.5%的股票被卖空。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, Jefferies Financial Group cut their price target on shares of Finch Therapeutics Group from $29.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, April 4th.
另外,杰富瑞金融集团在4月4日星期一的一份报告中将芬奇治疗集团的股票目标价从29.00美元下调至17.00美元,并对该股设定了“买入”评级。
Institutional Trading of Finch Therapeutics Group
芬奇治疗集团的机构交易
A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Finch Therapeutics Group by 19.4% during the 1st quarter. Renaissance Technologies LLC now owns 45,000 shares of the company's stock valued at $226,000 after buying an additional 7,314 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Finch Therapeutics Group by 2.3% during the 1st quarter. BlackRock Inc. now owns 404,931 shares of the company's stock valued at $2,038,000 after buying an additional 9,149 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Finch Therapeutics Group by 53.6% during the 1st quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company's stock valued at $189,000 after buying an additional 13,128 shares in the last quarter. Lake Street Advisors Group LLC boosted its holdings in shares of Finch Therapeutics Group by 16.2% during the 4th quarter. Lake Street Advisors Group LLC now owns 739,136 shares of the company's stock valued at $7,369,000 after buying an additional 102,941 shares in the last quarter. Finally, Light Street Capital Management LLC boosted its holdings in shares of Finch Therapeutics Group by 1.8% during the 4th quarter. Light Street Capital Management LLC now owns 811,731 shares of the company's stock valued at $8,093,000 after buying an additional 14,400 shares in the last quarter. Institutional investors own 22.68% of the company's stock.
多家对冲基金最近调整了对该业务的持股。文艺复兴技术有限责任公司在第一季度增持了芬奇治疗集团19.4%的股票。复兴科技有限责任公司现在拥有4.5万股该公司的股票,价值22.6万美元,在上个季度又购买了7314股。贝莱德股份有限公司在第一季度增持了芬奇治疗集团的股票2.3%。贝莱德股份有限公司目前持有该公司404,931股股票,价值2,038,000美元,该公司在上个季度又购买了9,149股。Qube Research&Technologies Ltd在第一季度增持了芬奇治疗集团的股票53.6%。Qube Research&Technologies Ltd现在拥有37,631股该公司股票,价值18.9万美元,上个季度又购买了13,128股。Lake Street Advisors Group LLC在第四季度增持了芬奇治疗集团的股票16.2%。Lake Street Advisors Group LLC现在拥有该公司739,136股股票,价值7,369,000美元,上个季度又购买了102,941股。最后,Light Street Capital Management LLC在第四季度增持了芬奇治疗集团1.8%的股票。Light Street Capital Management LLC现在拥有811,731股该公司股票,价值8,093,000美元,上个季度又购买了14,400股。机构投资者持有该公司22.68%的股票。
Finch Therapeutics Group Stock Performance
芬奇治疗集团股票表现
Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $0.35 million during the quarter. Finch Therapeutics Group had a negative net margin of 448.35% and a negative return on equity of 33.13%. As a group, research analysts predict that Finch Therapeutics Group will post -1.98 EPS for the current year.
芬奇治疗集团(纳斯达克代码:FNCH-GET Rating)最近一次发布季度收益报告是在5月16日星期一。该公司公布了该季度每股收益(0.52美元)。该公司本季度营收为35万美元。芬奇治疗集团的净利润率为负448.35%,净资产回报率为负33.13%。研究分析师预测,作为一个整体,芬奇治疗集团本年度的每股收益将达到1.98美元。
Finch Therapeutics Group Company Profile
芬奇治疗集团公司简介
(Get Rating)
(获取评级)
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.
芬奇治疗集团公司是一家临床阶段的微生物组治疗公司,在美国开发一种新型的口服生物药物。该公司的主要候选药物是CP101,这是一种口服微生物胶囊,正处于第三阶段临床试验,用于治疗反复发作的艰难梭菌感染患者,以及治疗慢性乙肝病毒。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
- MarketBeat: Week in Review 7/11 – 7/15
- Should You Have These Two Banks In Your Portfolio?
- Is Coupang's Stock On The Verge Of A Turnaround?
- Why Shopify Stock Split...And is as Shoppable as Ever
- Verint Systems Stock is a Customer Engagement Play
- 免费获取StockNews.com关于芬奇治疗集团(FNCH)的研究报告
- MarketBeat:回顾一周7/11-7/15
- 你的投资组合中应该有这两家银行吗?
- Coupang的股票即将翻身吗?
- 为什么Shopify股票拆分...并一如既往地适合购物
- Verint Systems Stock是一场客户互动活动
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受芬奇治疗集团每日新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收芬奇治疗集团和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧